{
    "symbol": "EBS",
    "quarter": 1,
    "year": 2022,
    "date": "2022-04-28 21:47:05",
    "content": " Other notable items in the quarter include, anthrax vaccine sales of $104 million, higher than the prior year due to timing of deliveries of AV7909 to the U.S. government\u2019s strategic national stockpile; ACAM2000 sales of $14 million, reflecting deliveries to non-U.S. government customers, seeking to protect against the threat of smallpox; nasal naloxone product sales of $93 million, higher than the prior year and comprised of strong unit sales of branded NARCAN to U.S. public interest and Canadian customers, as well as solid contributions from sales of the authorized generic product licensed to Sandoz, which launched in December 2021."
}